
Reactosome
Biotech, Rewritten from the Nucleus Out
San Francisco, United States · Founded 2023
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2023
- Business Model
- B2B
- Website
- reactosome.com
- Last Round
- AngelMar 2024
- Rounds
- 1
About
Reactosome is a synthetic cell platform company pioneering programmable molecular compartments called Synthetic Nuclei that combine precision intracellular delivery with on-site RNA and protein production. Unlike viral vectors or lipid nanoparticles, Reactosome proprietary platform can transport complex cargos including large genes and enzymes, enabling localized RNA expression and protein production directly inside the cell. The platform is designed for three application areas: gene therapies for structural and metabolic disorders, localized protein production for regenerative medicine, and bioproduction for pharma, cosmetics, and industrial biotech. The company operates across San Francisco and Berlin.
Summary
Reactosome is a Biotech company based in San Francisco, United States, founded in 2023. Its most recent funding was an Angel round in Mar 2024. Investors include SOSV.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2024
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...

Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...